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Spontaneous Non-Traumatic Stress Fractures in Bilateral 
Femoral Shafts in a Patient Treated with Bisphosphonates
Dong Yeob Shin, Cheol Ryong Ku, Kyung Min Kim, Han Seok Choi, Yumie Rhee, Eun Jig Lee, and Sung-Kil Lim
Department of Internal Medicine and Endocrine Research Institute, Yonsei University College of Medicine, Seoul, Korea
Bisphosphonates are potent inhibitors of bone resorption and widely used to treat osteoporosis. Extensive studies have 
shown that therapy with bisphosphonates improves bone density and decreases fracture risk. However, concerns have 
been raised about potential over-suppression of bone turnover during long-term use of bisphosphonates, resulting in 
increased susceptibility to and delayed healing of non-spinal fractures. We report a patient who sustained non-traumatic 
stress fractures in bilateral femoral shafts with delayed healing after long-term bisphosphonate therapy. She underwent 
open reduction and surgical internal fixation. Although bisphosphonates effectively prevent vertebral fractures, and their 
safety has been tested in randomized trials, we must emphasize the need for awareness of the possibility that long-term 
suppression of bone turnover with bisphosphonates may eventually lead to an accumulation of fatigue-induced damage 
and adverse skeletal effects such as delayed fracture healing. 
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INTRODUCTION
Bisphosphonates are have been used for many years for 
a variety of conditions including Paget’s disease, osteopo-
rosis, multiple myeloma, and hypercalcemia of malignan-
cy. They decrease bone resorption and hypercalcemia and 
reduce the osteolysis of bone metastasis [1]. A number of 
randomized clinical trials have shown that they increase 
bone density and reduce the incidence of fractures in os-
teoporosis [2]. Although bisphosphonates are generally 
safe and effective, concerns have been raised about the 
potential risk of over-suppression of bone turnover dur-
ing long-term use. Odvina et al. [2] have reported on nine 
patients who sustained spontaneous non-spinal fractures 
while on alendronate therapy. Schneider [3] also described 
a 59-year-old previously healthy woman who experienced 
two non-traumatic stress fractures of the femur, 4 years 
apart, while on alendronate therapy. Armamento-Villareal 
et al. [4] reported a 35-year-old man who, after 6 years of 
treatment with 10 mg/day alendronate, had a sub-trochan-
teric fracture of the right femur after mild trauma. A bone 
biopsy showed a lack of osteoid on trabecular surfaces and 
an absence of tetracycline labeling, suggesting marked 
suppression of bone turnover. 
Here, we describe a 63-year-old Korean woman who 
presented with non-traumatic spontaneous diaphyseal 
fractures of both femurs and delayed fracture healing after 
5 years bisphosphonate therapy. 
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CASE REPORT
A 63-year-old woman was admitted to hospital because 
of severe pain in both anterior thighs for 5 months. The 
pain had been aggravating, and she could no longer walk 
by herself. When she presented with osteoporosis and 
degenerative arthritis 5 years ago, she started to take alen-
dronate 70 mg/wk, alfacalcidol 0.5 μg/day and calcium 
citrate 1,900 mg/day. Three years later, she switched to 
risedronate 35 mg/wk and calcitriol 0.25 μg/day because 
of dyspepsia. She had total abdominal hysterectomy with 
bilateral salpingo-oophorectomy 35 years ago due to endo-
metriosis. 
At the time of admission, her height was 147 cm, and 
her weight was 54 kg; these had been 158 cm and 55 kg in 
her fourth decade. There was no history of any trauma, 
falling, or medication that predisposed to osteoporosis 
and fracture. She had no history of smoking and drink-
ing alcohol. Her lifestyle had not been sedentary because 
she had to work in the fields for her living. Her diet was 
mainly composed of grains and vegetables. She ate fish 
once weekly and ate few dairy products. Physical examina-
tion revealed blood pressure of 100/80 mmHg, pulse rate 
of 80 beats/min, respiratory rate of 20 breaths/min, and 
body temperature was 36.5°C. Cardiac and abdominal ex-
aminations were normal. Here walking pattern could not 
be documented because of her pain. Both upper and lower 
extremities showed no structural abnormality or muscle 
weakness. There was kyphosis of her upper back. There 
was severe tenderness on both distal thighs. Straight leg 
raising and femoral nerve stretching tests were both nega-
tive. 
Laboratory tests showed hemoglobin 12.2 g/dL, white 
blood cell count 4,910/mm
2, platelet count 334,000/μL, 
serum calcium 9.3 mg/dL, serum phosphorus 3.2 mg/dL, 
total protein 7.5 g/dL, serum albumin 4.7 g/dL, uric acid 5.1 
mg/dL, and alkaline phosphatase 72 IU/L. Daily urinary 
calcium excretion was 369.2 mg (normal, 70 to 180), and 
daily urinary phosphorous excretion was 959.92 mg (nor-
mal, 400 to 1,300). Serum protein electrophoresis showed 
no abnormality. Serum parathyroid hormone (PTH) was 
18.92 pg/mL (normal, 10 to 65), and 25-(OH)-vitamin D, 
determined by commercially available radioimmunoas-
say kit (DiaSorin, Stillwater, MN, USA), was 15.33 ng/mL 
(normal, 9.0 to 37.6). Osteocalcin was 18.93 ng/mL (normal 
postmenopausal, 19.6 to 41.2), serum C-telopeptide, 0.301 
ng/mL (normal postmenopausal, 1.008), and urine N-telo-
peptide was 55.7 nBCE/mM Cr (normal postmenopausal, 
6.0 to 125.72).
Simple X-rays of the thoracic and lumbar spine showed 
diffusely decreased vertebral height with osteoporosis and 
multiple compression fractures of T4, T5, T11, L1, L2, L4, 
and L5 vertebrae. There was no additional compression 
spinal fracture compared with X-rays taken 2 years ear-
lier (Fig. 1). The most recent bone mineral density (BMD), 
measured by dual-energy X-ray absorptiometry (QDR-
4500A, Hologic, Waltham, MA, USA), showed a T-score at 
the third lumbar vertebra of –3.8 and a total hip T-score 
of –3.3 (Table 1). All of the results showed severe osteo-
porosis, and no improvement in BMD was seen, despite 
bisphosphonate treatment. Whole spine magnetic reso-
nance imaging revealed multiple compression fractures 
in the T4, T5, T11, L1, L2, L4, and L5 vertebral bodies 
and diffuse disk bulging at L2–3, L3–4, and L4–5, with 
degenerative changes of facet joints and thickening of liga-
mentum flavum. There was no definite evidence of thecal 
Figure 1. Spine X-rays taken in 2004 (A) and 2006 (B) showed diffusely decreased vertebral height with osteopenia and multiple com-
pression fractures of T4, T5, T11, L1, L2, L4, and L5 vertebrae. There was no evidence of any additional occurrence of vertebral fracture. 
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sac compression. A whole-body bone scan, which was ob-
tained 2 hours after injecting technetium-99m hydroxy-
methylene diphosphonate (HDP) intravenously, showed 
intense uptake at both distal femurs. Simple X-rays also 
showed fracture lines in both distal femur shafts, compat-
ible with sites of pain (Fig. 2). 
After spinal nerve block with walking rehabilitation 
therapy was done for pain control, pain was not improved. 
Therefore, we speculated that the delayed fracture healing 
of both distal femurs due to the long-term bisphospho-
nates therapy was the main cause of the pain. Bisphospho-
nate therapy was discontinued. However, the pain contin-
ued, and the fracture lines seemed to become aggravated 
and showed delayed fracture healing. Normally, femoral 
fracture takes about 6 weeks to be healed completely. 
However, the patient had surgical internal fixation at both 
femoral diaphyses because of non-union of the femoral 
fractures even after 6 months of observation without 
bisphosphonates (Fig. 3). The elapsed time from the first 
visit to surgical internal fixation was 7 months. During 
the operation, severe osteoporotic fracture was noted, but 
structural displacement was mild. Bone biopsy performed 
Figure 2. Whole body bone scan (A) and simple X-rays of both fe-
murs (B) showing the fracture lines at the site of pain. 
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Figure 3. Simple X-rays of both femurs after open reduction 
and internal fixation.
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Table 1. Femoral bone mineral density (BMD) measured before and after bisphosphonate treatment in 2001 and 2005
Measured site 
2001/05/30 2004/04/29 2005/07/01
BMD, g/cm
2 T-score BMD, g/cm
2 T-score BMD, g/cm
2 T-score  
Total hip 0.475 -3.3 0.514 -2.9 0.474 -3.3
Femoral neck  0.447 -3.3 0.481 -3.0 0.415 -3.6Shin DY, et al. Fracture during bisphosphonate therapy    101
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with surgical fixation showed decreased trabecular bone 
with massive fibrosis in the marrow space. 
DISCUSSION
Alendronate, risedronate, ibandronate, and zoledronate, 
which are classified as amino-bisphosphonates, have much 
higher potency because they contain nitrogen in their 
side chain [1]. However, concerns have been raised about 
potential risk of over-suppression of bone remodeling dur-
ing long-term use. Prolonged use of bisphosphonates may 
suppress bone turnover to the point that micro-damage 
persists and accumulates. In experimental animals, 
alendronate has been shown to inhibit normal repair of 
micro-damage arising from marked suppression of bone 
turnover, which results in macro-cracks [5]. Chronic over-
suppression of bone turnover by bisphosphonates may 
allow secondary mineralization to continue, resulting in 
hard, brittle bone with an increased risk for fracture [6]. 
Other supportive evidence on over-suppression includes 
several reports of jaw osteonecrosis in patients treated 
with high doses of bisphosphonates [1]. Recently, Odvina et 
al. [2] reported nine patients (eight postmenopausal wom-
en and one man) who sustained unusual spontaneous non-
spinal fractures while on alendronate therapy (10 mg/day 
or 70 mg/wk) for 3–8 years. Six of the nine patients had 
delayed or absent fracture healing for 4 months to 2 years 
during alendronate therapy, and four showed delayed frac-
ture healing for 8–12 months even after discontinuation 
of alendronate. Although co-administration of estrogen or 
glucocorticoids appears to be a predisposing factor, this 
apparent complication also occurred with bisphospho-
nate monotherapy. All the patients had trabecular bone 
biopsies. All patients showed markedly suppressed bone 
formation, with reduced or absent osteoblastic activities.  
Our case report described a woman who experienced 
non-traumatic spontaneous stress fractures while on 
bisphosphonate therapy and non-union of the femoral 
shaft fracture despite discontinuation of bisphosphonates. 
We were able to ensure good adherence to medication 
by her self-report and serial measurements of urinary 
N-telopeptide, one of the bone turnover markers, which 
showed a decrease of 62.5%, from 40.8 to 15.3 nBCE/mM 
Cr, during the first 3 months after initiation of bisphos-
phonate therapy and similar levels afterwards. Therefore, 
this case had the possibility of delayed fracture healing 
due to suppression of bone turnover by long-term use of 
bisphosphonates. Other possible causes of insufficiency or 
pathological fracture include osteoporosis-include osteo-
malacia, osteogenesis imperfecta, bone tumors (primary 
or metastatic), and Paget’s disease of bone. However, she 
had no definite clinical and laboratory evidence of such 
diseases. Bisphosphonates are incorporated into the skel-
eton without degradation. Therefore, their skeletal half-
life is remarkably long. The residual effect on bone density 
is known to remain for 3 years after drug withdrawal [7], 
and it is possible that the suppressive effect of bisphos-
phonates on bone resorption might also be cumulative 
over time. Therefore, close monitoring and assessment of 
fracture healing after internal fixation in this patient was 
mandatory, considering the risk of re-fracture. The fixed 
pins were maintained, and she showed full union status 6 
months after internal fixation. 
In this patient, the biochemical markers such as N- and 
C-telopetides and serum osteocalcin showed normal levels 
and did not reveal magnitude of the suppression of bone 
turnover. The case reports of Odvina et al. [2] and Chavas-
sieux et al. [8] have shown similar results. The discordance 
between the histomorphometric and biochemical markers 
of bone turnover could be related to the variable degree 
of suppression at different skeletal sites, as the changes 
in biochemical markers are more reflective of changes in 
the whole skeleton [2]. Additionally, this patient showed 
somewhat elevated daily urinary calcium excretion, with 
normal serum calcium, phosphorus, and PTH level. The 
active vitamin D, calcitriol, was thought to be the cause of 
this hypercalciuria.
Although previous studies have shown the efficacy of 
bisphosphonates in the first 5 years of therapy in terms 
of improving bone density and reduced risk of fractures 
[9], additional studies are needed to determine how long 
bisphosphonates can safely be given. Recently, Black et 
al. [10] have compared the effects of discontinuing alen-
dronate treatment after 5 years versus continuing for 10 
years. The results confirmed the safety of alendronate for 
up to 10 years, including no increased fracture risk with 
long-term use [10]. However, even those who discontinued 
alendronate after 5 years showed no higher fracture risk, 
other than for clinical vertebral fractures, compared with 
those who continued alendronate. These results suggest 
that discontinuation of alendronate for up to 5 years does 102    The Korean journal of Internal Medicine Vol. 27, No. 1, March 2012
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not appear to significantly increase fracture risk, except 
for the patients at very high risk of vertebral fractures. 
Furthermore, considering some definitive case reports, 
we must emphasize the need for awareness of recent con-
troversies about the effect of long-term reduction of bone 
turnover on bone strength, especially the occurrence of 
awkward fractures at an unexpected site, as in this patient. 
The benefits of prolonged use of bisphosphonates must be 
carefully weighed against the potential adverse effects of 
over-suppression of bone metabolism. 
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